BridgeBio Plunges 67% After Disappointing Results of Acoramidis Test Study
(BridgeBio) BridgeBio Pharma shares fell 67% in premarket on Monday after the company announced that a stage 3 study for its acoramidis drug failed to meet its primary endpoint at…